Key Insights

Highlights

Treatment Research

2 treatments under study, led by Nmd670

Research Leaders

5 sponsors active, led by Alira Health

Related Conditions

Often studied with 17 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 3 (1)

Trial Status

Recruiting3
Terminated1

Clinical Trials (4)

Showing 4 of 4 trials
NCT06414954Phase 2Recruiting

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

NCT07761026Recruiting

AXIS MG Patient Registry

NCT06617741Recruiting

Myasthenia Gravis Foundation of America Global MG Patient Registry

NCT03579966Phase 3TerminatedPrimary

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Showing all 4 trials

Research Network

Common Treatments

  • Nmd6701
  • Amifampridine Phosphate1

Active Sponsors

  • Alira Health2
  • NMD Pharma A/S1
  • Catalyst Pharmaceuticals, Inc.1
  • Autoimmune Neurology Alliance1
  • Myasthenia Gravis Foundation of America1

Top Investigators

Related Conditions

  • Myasthenia Gravis3
  • Myasthenia Gravis Generalized2
  • Myasthenia Gravis Thymectomy2
  • Achr Myasthenia Gravis2
  • Myasthenia Gravis Generalised2

Activity Timeline